LEADER 04100nam  22006015  450 
001 9910350356103321
005 20200705045645.0
010   $a981-13-8019-8
024 7 $a10.1007/978-981-13-8019-8
035   $a(CKB)4100000008876856
035   $a(DE-He213)978-981-13-8019-8
035   $a(MiAaPQ)EBC5811816
035   $a(PPN)238486885
035   $a(EXLCZ)994100000008876856
100   $a20190702d2019      u|         0
101 0 $aeng
135   $aurnn#008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aHistone Deacetylase Inhibitors ? Epidrugs for Neurological Disorders /$fby Shabir Ahmad Ganai
205   $a1st ed. 2019.
210  1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019.
215   $a1 online resource (XVII, 93 p. 8 illus., 5 illus. in color.)
311   $a981-13-8018-X 
327   $aChapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.
330   $aThis book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors? therapeutic efficacy against various neurological complications.
606   $aNeurosciences
606   $aPharmacology
606   $aGenetics
606   $aProteins 
606   $aPosttranslational modification
606   $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
606   $aGenetics and Genomics$3https://scigraph.springernature.com/ontologies/product-market-codes/L32000
606   $aProtein Science$3https://scigraph.springernature.com/ontologies/product-market-codes/L14040
606   $aPosttranslational Modification$3https://scigraph.springernature.com/ontologies/product-market-codes/L14090
615  0$aNeurosciences.
615  0$aPharmacology.
615  0$aGenetics.
615  0$aProteins .
615  0$aPosttranslational modification.
615 14$aNeurosciences.
615 24$aPharmacology/Toxicology.
615 24$aGenetics and Genomics.
615 24$aProtein Science.
615 24$aPosttranslational Modification.
676   $a612.8
700   $aGanai$b Shabir Ahmad$4aut$4http://id.loc.gov/vocabulary/relators/aut$0904016
906   $aBOOK
912   $a9910350356103321
996   $aHistone Deacetylase Inhibitors ? Epidrugs for Neurological Disorders$92020945
997   $aUNINA